Editorial board member Paolo Ascierto from National Tumor Institute “Fondazione G. Pascale”, Naples, Italy, discusses the use of molecular markers to inform therapy in melanoma and important research approaches to advance treatment.
1. How are personalised strategies impacting the treatment of melanoma? (0:11)
2. What molecular markers have been validated to inform selection of therapy? (1:04)
3. What is the main focus of current research investigating combinations of therapy in melanoma? (2:16)
4. What have been the latest advances in systemic adjuvant treatment of stage II/III melanoma? (4:20)
5. What do you see as the most important advance in melanoma treatment in recent years? (5:35)
Speaker disclosures: Paolo Ascierto has provided an advisory role for BMS, Roche, MSD, Array, Novartis, Amgen, EMD Serono, Pierre-Fabre, Incyte, Genmad, New Link Genetics, Medimmune, AstraZeneca and Sindax. He has also received research funds from BMS, Roche and Array.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Share this Video
Related Videos In Dermatological Cancer
Paolo A Ascierto,ESMO 2020 – The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study
Editorial board member, Dr Paolo A Ascierto, joins us at the Virtual 2020 ESMO Congress to discuss immunotherapy in BRAF-mutated metastatic melanoma and the major findings from the The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study. Questions What is the rationale for the combination of targeted and immunotherapy in the treatment of BRAF-mutated metastatic […]
Ana Maria Arance Fernandez, ESMO 2020 – Lenvatinib plus Pembrolizumab for Advanced Melanoma: Initial Results of LEAP-004
touchONCOLOGY meets with Dr Ana Maria Arance Fernandez at ESMO 2020 to discuss findings from the LEAP-004 trial, and the role lenvatinib plus pembrolizumab can play in the treatment of advanced melanoma. The late-breaking abstract ‘Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: initial results of […]
Dirk Schadendorf, ESMO 2018 – Encorafenib plus Binimetinib for BRAF-mutant Metastatic Melanoma
In this interview, filmed at ESMO 2018, Professor Schadendorf discusses the use of encorafenib plus binimetinib for BRAF-mutant metastatic melanoma. Questions: 1. Could you tell us a little about the efficacy and safety findings of the COLUMBUS study that have led to the recent European approval of encoranefib plus binimetanib for BRAF-mutant metastatic melanoma? (0:11) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!